CREEK is a Multicenter Retrospective Study to Understand the Clinical Characteristics, Treatment Pathway and Resource Utilization for Patients With Chronic Lymphocytic Leukemia in International Region.

Criterios de inclusión

• Primary diagnosis of Chronic Lymphocytic Leukemia (CLL)
• Initiated CLL treatment (including 1st line, 2nd line, or Subsequent lines of treatment) within the period between 01 June 2016, and 12 months before data collection
• \- For GCC pilot cohort patients: treatment-naive CLL patients diagnosed between 01 June 2016, and 12 months before data collection.
• Available medical records at the participating site reflecting at least 12 months of follow-up after starting on treatment (except in the case of the participant death within one year following treatment initiation).
• Provision of informed consent by the patient or next of kin/legal representative (for deceased patients at study entry, unless a waiver was granted), according to local regulations.
• Adult male or female ≥18 years old at the time of diagnosis or according to the age of majority as defined by local regulations).
• Any diagnosis of B-cell malignancies other than CLL.
• Current or prior use of "acalabrutinib" treatment.
• Currently/previously receiving treatment in an interventional clinical trial at the time of entry into this study for indications CLL.